Bextra Withdrawal Will Test Pfizer’s Liability Defense Record
Executive Summary
The withdrawal of the COX-2 inhibitor Bextra will test Pfizer's reputation for withstanding product liability litigation
You may also be interested in...
Celebrex, Bextra Ads Draw Fire From FDA; Reminder Of “Reminder” Ad Rules
An FDA "untitled" letter to Pfizer on Celebrex and Bextra is the agency's second recent objection to the company's interpretation of the boundaries of "reminder" ads
Bextra Meta-Analysis Affirms Safety Profile, Pfizer Tells Physicians
A meta-analysis of Bextra (valdecoxib) clinical trials in osteoarthritis and rheumatoid arthritis show the agent has a lower incidence of myocardial infarctions compared to traditional NSAIDs, Pfizer maintains in Dec. 2 "medical information letters.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011